PriceTargets.com logo

iRhythm Technologies - IRTC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $162.27
  • Forecasted Upside: 23.87 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$131.00 As of 10/3/2022 01:41 PM ET
▲ +5.72 (4.57%)

This chart shows the closing price for IRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

Analyst Price Target is $162.27
▲ +23.87% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $162.27, with a high forecast of $198.00 and a low forecast of $105.00. The average price target represents a 23.87% upside from the last price of $131.00.

This chart shows the closing price for IRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in iRhythm Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/4/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/2/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022Morgan StanleyLower TargetOverweight$190.00 ➝ $172.00Low
9/22/2022JPMorgan Chase & Co.Boost TargetOverweight$185.00 ➝ $190.00Low
9/2/2022Canaccord Genuity GroupBoost TargetBuy$185.00 ➝ $198.00Low
9/2/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$185.00 ➝ $198.00Low
8/9/2022CitigroupBoost Target$157.00Low
8/5/2022BTIG ResearchBoost TargetBuy$155.00 ➝ $178.00Low
6/24/2022BTIG ResearchLower TargetBuy$180.00 ➝ $155.00Low
6/22/2022JPMorgan Chase & Co.Reiterated RatingOverweight$183.00 ➝ $135.00Low
6/16/2022Truist FinancialLower TargetBuy$200.00 ➝ $165.00High
6/9/2022CitigroupDowngradeBuy ➝ Neutral$180.00 ➝ $155.00High
5/6/2022CitigroupBoost Target$175.00 ➝ $180.00High
4/5/2022Wolfe ResearchInitiated CoverageUnderperform$105.00High
4/4/2022JPMorgan Chase & Co.Boost TargetOverweight$156.00 ➝ $192.00Medium
2/24/2022Morgan StanleyLower TargetOverweight$167.00 ➝ $151.00High
2/24/2022Needham & Company LLCUpgradeHold ➝ Buy$135.00High
1/27/2022JPMorgan Chase & Co.Boost TargetOverweight$116.00 ➝ $156.00Medium
1/18/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$129.00 ➝ $167.00High
1/14/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$125.00 ➝ $160.00Low
1/14/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$125.00 ➝ $160.00Low
1/14/2022CitigroupBoost TargetBuy$120.00 ➝ $165.00Low
1/13/2022Truist FinancialBoost Target$130.00 ➝ $185.00Low
1/12/2022Robert W. BairdBoost Target$110.00 ➝ $137.00Low
1/12/2022BTIG ResearchUpgradeNeutral ➝ Buy$170.00Low
1/11/2022OppenheimerUpgradeMarket Perform ➝ Outperform$150.00High
1/7/2022Morgan StanleyBoost TargetEqual Weight$114.00 ➝ $129.00Medium
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $116.00High
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00High
11/8/2021Morgan StanleyBoost TargetEqual Weight$77.00 ➝ $114.00Low
11/5/2021CitigroupBoost TargetNeutral$60.00 ➝ $120.00Medium
10/14/2021JPMorgan Chase & Co.Boost TargetNeutral$55.00 ➝ $70.00Low
10/1/2021CitigroupBoost TargetNeutral$55.00 ➝ $60.00Low
8/6/2021CitigroupLower TargetNeutral$74.00 ➝ $55.00High
6/3/2021Morgan StanleyLower TargetEqual Weight$94.00 ➝ $85.00Low
6/2/2021Needham & Company LLCReiterated RatingHoldHigh
6/2/2021CitigroupDowngradeBuy ➝ NeutralHigh
4/20/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/19/2021BTIG ResearchReiterated RatingBuy ➝ NeutralN/A
4/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/13/2021Truist FinancialLower Target$220.00 ➝ $115.00Low
4/13/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
4/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$215.00 ➝ $95.00High
4/12/2021Robert W. BairdLower TargetNeutral$170.00 ➝ $80.00High
3/4/2021Colliers SecuritiesReiterated RatingBuy ➝ NeutralN/A
3/1/2021CitigroupLower TargetBuy$252.00 ➝ $195.00Low
2/28/2021Robert W. BairdReiterated RatingHoldLow
2/26/2021Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
2/4/2021BTIG ResearchLower TargetBuy$283.00 ➝ $210.00Low
2/1/2021Truist FinancialLower Target$265.00 ➝ $220.00Low
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
1/25/2021Morgan StanleyBoost TargetOverweight$227.00 ➝ $288.00High
1/21/2021BTIG ResearchBoost TargetBuy$235.00 ➝ $283.00High
12/15/2020Morgan StanleyLower TargetOverweight$230.00 ➝ $227.00High
12/10/2020William BlairReiterated RatingBuyMedium
12/3/2020Truist FinancialLower Target$265.00 ➝ $240.00Medium
12/3/2020Smith Barney CitigroupLower Target$275.00 ➝ $238.00Medium
12/3/2020Robert W. BairdLower TargetNeutral$220.00 ➝ $170.00High
12/2/2020Morgan StanleyLower TargetOverweight$270.00 ➝ $230.00High
11/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/17/2020Needham & Company LLCReiterated RatingHoldHigh
11/6/2020Truist FinancialBoost Target$200.00 ➝ $265.00Low
11/6/2020Morgan StanleyBoost TargetOverweight$259.00 ➝ $270.00Low
11/6/2020OppenheimerReiterated RatingBuy$200.00 ➝ $250.00High
10/12/2020BTIG ResearchBoost Target$130.00 ➝ $160.00Low
9/11/2020Needham & Company LLCInitiated CoverageHoldLow
9/1/2020Robert W. BairdInitiated CoverageNeutral$220.00Medium
8/25/2020CitigroupBoost TargetBuy$215.00 ➝ $250.00Low
8/7/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$200.00High
8/5/2020CitigroupBoost TargetBuy$147.00 ➝ $200.00High
8/5/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$125.00 ➝ $140.00Low
5/8/2020Morgan StanleyBoost TargetOverweight$114.00 ➝ $142.00Low
5/8/2020SunTrust BanksBoost TargetBuy$102.00 ➝ $130.00High
5/8/2020BTIG ResearchReiterated RatingBuy$130.00High
5/8/2020OppenheimerReiterated RatingHoldHigh
3/27/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $114.00High
3/27/2020CitigroupLower TargetBuy$120.00 ➝ $112.00High
3/4/2020CitigroupInitiated CoverageBuy$120.00Medium
2/5/2020BTIG ResearchInitiated CoverageBuy$90.00Low
1/9/2020William BlairInitiated CoverageOutperformHigh
1/7/2020SunTrust BanksInitiated CoverageBuy$102.00High
12/17/2019Morgan StanleyBoost TargetOverweight$101.00 ➝ $110.00Low
10/22/2019OppenheimerInitiated CoverageMarket PerformLow
8/1/2019JPMorgan Chase & Co.Boost TargetOverweight$110.00 ➝ $125.00High
7/31/2019BTIG ResearchSet TargetBuy$90.00N/A
5/8/2019BTIG ResearchBoost TargetPositive ➝ Buy$90.00High
4/3/2019BTIG ResearchUpgradeNeutral ➝ Buy$80.00Medium
2/20/2019Chardan CapitalDowngradeBuy ➝ Neutral$111.00 ➝ $104.00Low
2/13/2019Royal Bank of CanadaBoost TargetOutperform$109.00Low
2/13/2019JPMorgan Chase & Co.Boost Target$110.00Low
2/13/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$85.00 ➝ $101.00Medium
2/13/2019Northland SecuritiesReiterated RatingHold$75.00High
2/13/2019BTIG ResearchReiterated RatingHoldMedium
2/13/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$96.00 ➝ $105.00High
10/11/2018Morgan StanleyBoost TargetOverweight$92.00 ➝ $95.00High
9/6/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$117.00Medium
8/2/2018Dougherty & CoUpgradeSell ➝ NeutralHigh
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$86.00 ➝ $92.00High
8/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$100.00High
8/2/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$93.00 ➝ $96.00High
7/16/2018Dougherty & CoDowngradeNeutral ➝ SellMedium
7/10/2018BMO Capital MarketsBoost TargetOutperform$93.00High
6/13/2018Royal Bank of CanadaBoost TargetOutperform$91.00Medium
6/4/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$70.00 ➝ $86.00Low
4/16/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/14/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$76.00Medium
2/15/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$62.00 ➝ $67.00High
12/4/2017Royal Bank of CanadaInitiated CoverageOutperform$79.00High
12/1/2017Dougherty & CoInitiated CoverageNeutral ➝ NeutralMedium
11/3/2017Morgan StanleyBoost TargetOverweight$50.00 ➝ $65.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/5/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
7/5/2022
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
9/3/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $131.00
Low: $124.99
High: $132.69

50 Day Range

MA: $147.62
Low: $118.83
High: $160.42

52 Week Range

Now: $131.00
Low: $56.52
High: $169.54

Volume

8,900 shs

Average Volume

394,598 shs

Market Capitalization

$3.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, StockNews.com, Truist Financial Co., and Wolfe Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

11 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $162.27, suggesting a possible upside of 23.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting IRTC will reach $198.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $105.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRTC will outperform the market and that investors should add to their positions of iRhythm Technologies.
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

Other companies that are similar to iRhythm Technologies include ICU Medical, Integra LifeSciences, Haemonetics, Inari Medical and Axonics. Learn More about companies similar to iRhythm Technologies.

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is (415) 632-5700 and its investor relations email address is [email protected] The official website for iRhythm Technologies is www.irhythmtech.com. Learn More about contacing iRhythm Technologies investor relations.